![]() |
시장보고서
상품코드
1785341
세계의 조직학 및 세포학 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 검사 유형별, 제품별, 용도별, 지역별, 경쟁별(2020-2030년)Histology and Cytology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Examination, By Product, By Application, By Region and Competition, 2020-2030F |
세계의 조직학 및 세포학 시장은 2024년 173억 7,000만 달러로 평가되었으며, CAGR 13.19%로 확대되어 예측 기간에는 366억 1,000만 달러에 달할 것으로 예측되고 있습니다.
세포학은 세포의 구조, 기능 및 이해에 관한 생명 과학의 한 부문이며, 조직학은 생체의 세포와 조직의 현미경 해부학에 관한 것입니다. 조직학 및 세포학의 세계는 동물과 식물의 조직과 세포의 구조를 특히 현미경 수준에서 설명하기 위해 노력하고 있습니다. 세포 진단은 신속한 검사 속도, 정확성, 저렴한, 높은 질병 이환율 및 자궁 경부 스크리닝을위한 검사의 사용으로 매우 인기가 있습니다. 자궁경부 질환, 염증성 질환, 암, 자가면역 질환 등 많은 감염증과 세포성 질환의 진단이 조직학 및 세포학을 사용하여 조사되고 있습니다. 조직학 및 세포학 세계 시장은 이러한 임상 연구를 통해 많은 질병을 진단할 수 있기 때문에 헬스케어 산업에서 큰 성장을 이루고 있습니다. 조직학 및 세포학의 세계를 사용함으로써 자궁 경부 질환, 암, 이상 증식, 간염, 염증성 질환, 설사, 백혈병, 천연두, 광견병 등 많은 감염증을 확인할 수 있습니다. 상업적 관점에서 세포 진단 및 조직 진단은 진단 및 조사 절차에 사용됩니다. 시장 동향은 이러한 임상 처치에 대한 시약 및 키트 개발에 대한 제조업체의 선호와 함께 결정됩니다.
시장 개요 | |
---|---|
예측 기간 | 2026-2030년 |
시장 규모 : 2024년 | 173억 7,000만 달러 |
시장 규모 : 2030년 | 366억 1,000만 달러 |
CAGR : 2025-2030년 | 13.19% |
급성장 부문 | 세포학 |
최대 시장 | 북미 |
디지털 병리학, AI 지원 이미징, 자동 슬라이드 제작 등 진단 실험실에서 첨단 기술의 채용이 증가하고 있는 것이 세계 조직학 및 세포학 시장의 성장을 더욱 촉진하고 있습니다. 이러한 혁신은 진단 정확도를 높이고 수작업으로 인한 실수를 줄이고 워크플로우 효율을 향상시킵니다. 게다가 텔레파솔로지의 통합은 병리학자들이 원격으로 슬라이드를 검사할 수 있게 해주며, 이는 특히 농촌 지역과 서비스가 어려운 지역에서 유익하기 때문에 고품질의 진단에 대한 접근이 세계적으로 확대되고 있습니다.
암 이환율 증가
기술의 복잡성과 비용
리퀴드 바이옵시 및 순환 바이오마커
Global Histology and Cytology Market was valued at USD 17.37 billion in 2024 and is expected to reach USD 36.61 billion in the forecast period with a CAGR of 13.19% through 2030. Cytology is a branch of life science concerned with the structure, function, and understanding of cells, whereas histology is concerned with the microscopic anatomy of cells and tissues of life forms. Histology and cytology strive to explain the structure of animal and plant tissues and cells, particularly at the microscopic level. Cytology is quite popular due to its rapid examination rate, precision, and affordability, as well as the high disease prevalence and use of the test for cervix screening. The diagnosis of numerous infectious and cell-based disorders, such as cervical diseases, inflammatory diseases, cancer, and autoimmune diseases, is investigated using histology and cytology. The histology and cytology market has been witnessing massive growth in the healthcare industry as a number of diseases can be diagnosed through these clinical studies. With the aid of histology and cytology, a number of infectious diseases can be identified such as cervical disease, cancer, abnormal growth, hepatitis, inflammatory diseases, diarrhea, leukemia, smallpox, rabies etc. From the commercial perspective, cytology and histology are used in the diagnostic and research procedure. The market trends are determined along with the manufacturer's preference for the development of reagents and kits for these clinical procedures.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 17.37 Billion |
Market Size 2030 | USD 36.61 Billion |
CAGR 2025-2030 | 13.19% |
Fastest Growing Segment | Cytology |
Largest Market | North America |
The increasing adoption of advanced technologies in diagnostic laboratories, such as digital pathology, AI-assisted imaging, and automated slide preparation, is further propelling the growth of the global histology and cytology market. These innovations enhance diagnostic accuracy, reduce manual errors, and improve workflow efficiency. Additionally, the integration of telepathology allows pathologists to remotely examine slides, which is especially beneficial in rural or underserved areas, thereby expanding access to high-quality diagnostics globally.
Key Market Drivers
Increasing prevalence of cancer
The rising global cancer burden is a major factor accelerating the growth of the Global Histology and Cytology Market. These medical disciplines, which focus on the microscopic examination of cells and tissues, are crucial for early and accurate cancer diagnosis. As cancer incidence continues to climb, particularly among aging populations, the demand for histopathological and cytological evaluations is growing rapidly. According to the International Agency for Research on Cancer (IARC), in 2022 there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally figures expected to increase substantially in the coming decades.
Furthermore, the number of cancer screening procedures is rising, particularly in emerging economies with expanding healthcare infrastructure. Cytological methods such as the Pap smear remain essential for cervical cancer screening. According to the World Health Organization (WHO), over 90% of cervical cancer cases are preventable and treatable if detected early and managed appropriately placing histology and cytology at the heart of global cancer control strategies. The increased use of biopsy techniques to assess tumors has also led to a surge in histopathological evaluations, further driving market demand. Combined with advances in digital pathology, AI-powered diagnostics, and molecular cytology, these trends ensure strong growth for histology and cytology technologies in oncology.
In addition to diagnostics, the role of histology and cytology in therapeutic monitoring is gaining prominence. As more cancer patients undergo treatments like chemotherapy, immunotherapy, or targeted therapy, regular assessment of tissue samples helps monitor treatment response and detect any recurrence or resistance. This has fueled the integration of advanced cytological imaging systems and histological staining technologies in clinical laboratories and hospitals. The demand for accurate pathological interpretation has also led to growing collaborations between hospitals and diagnostic centers, further expanding access to histology and cytology services.
Key Market Challenges
Technological Complexity and Costs
Advanced histology and cytology technologies often require significant upfront investments in terms of equipment, software, training, and infrastructure. This can be a barrier for smaller clinics, hospitals, and research facilities with limited financial resources. The high initial investment can lead to slower adoption rates, especially in regions with budget constraints. Utilizing complex histology and cytology technologies requires a skilled workforce with specialized training. Training pathologists, technicians, and clinicians to effectively use and interpret data from these technologies can be time-consuming and costly. The scarcity of skilled personnel can further impede technology adoption. Technologically advanced equipment typically requires regular maintenance and updates to ensure optimal performance. The costs associated with maintenance, repairs, and software updates can add to the overall expenses for healthcare institutions. This ongoing financial commitment can be a deterrent, particularly for smaller facilities. Integrating new technology into existing healthcare systems and workflows can be challenging. Compatibility issues with existing systems and processes may arise, requiring additional investments in software development and integration solutions. These challenges can delay technology implementation and adoption.
Key Market Trends
Liquid Biopsies and Circulating Biomarkers
Liquid biopsies involve the analysis of biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs), present in blood or other bodily fluids. They enable early detection of diseases, including cancer, even before traditional symptoms manifest. This capability drives the demand for histology and cytology services that can identify and analyze these biomarkers accurately. Unlike traditional tissue biopsies, which require invasive procedures, liquid biopsies are minimally invasive. This approach reduces patient discomfort, risk, and recovery time. As liquid biopsies gain prominence, the demand for traditional histological and cytological procedures might decline for certain applications, but histology and cytology techniques are still essential for validating liquid biopsy results and providing comprehensive diagnoses. Liquid biopsies are often used in conjunction with traditional histology and cytology techniques. They can provide additional information about tumor heterogeneity, genetic mutations, and treatment responses that might not be apparent through tissue biopsies alone. The integration of liquid biopsy data enhances the overall diagnostic accuracy and treatment decision-making process. Circulating biomarkers provide valuable information about a patient's tumor characteristics, enabling the development of personalized treatment strategies. This demand for personalized medicine supports the growth of the histology and cytology market, as these techniques remain essential for understanding tissue-level details and providing comprehensive patient care.
In this report, the Global Histology and Cytology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Histology and Cytology Market, By Type of Examination:
Histology and Cytology Market, By Product:
Histology and Cytology Market, By Application:
Histology and Cytology Market, By Region:
Company Profiles: Detailed analysis of the major companies present in the Global Histology and Cytology Market.
Global Histology and Cytology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: